Discontinued — last reported Q1 '25
Business Segments · Goodwill, Acquired During Period
Covance Drug Development — Goodwill, Acquired During Period
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ1 2014
Last reportedQ1 2025Apr 29, 2025
Rolls up toGoodwill Additions
How to read this metric
Higher values indicate aggressive inorganic growth strategies within the drug development market.
Detailed definition
The value of goodwill added to the balance sheet specifically from business combinations completed during the current re...
Peer comparison
Common in CROs and laboratory services companies pursuing consolidation.
Metric ID:
lh_segment_covance_drug_development_goodwill_acquired_during_periodHistorical Data
10 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $53.30M | $143.10M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | — | +168.5% | -100.0% | — | — | — | — | — |
Range$0.00 – $143.10M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — goodwill, acquired during period?
- Labcorp Holdings (LH) reported covance drug development — goodwill, acquired during period of $0.00 in Q1 2025.
- What does covance drug development — goodwill, acquired during period mean?
- Goodwill added to the segment's balance sheet from new acquisitions during the year.